Claim Missing Document
Check
Articles

Found 13 Documents
Search

DRUG THERAPY IN PATIENTS WITH GRADE 4 DEXTRA HIP OSTEOARTHRITIS WITH COMORBID HYPERTENSION AND TYPE 2 DIABETES MELLITUS Astiani, Rangki; Piter, Piter; Anggraeni, Ria; Luthfiana, Farisa; Sari, Dini Permata; Ramatillah, Diana Laila; Khan, Khasif
SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Vol 10, No 2 (2025)
Publisher : Universitas 17 Agustus 1945 Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52447/scpij.v10i2.8977

Abstract

Osteoarthritis (OA) is a chronic degenerative disease that affects the joints, especially heavy joints such as the knees and hips. OA often causes chronic pain and limited mobility, which is even more complex when accompanied by comorbid hypertension and type 2 diabetes mellitus. These comorbidities increase the risk of pharmacotherapy side effects and drug interactions, requiring a multidisciplinary approach and careful clinical pharmacy monitoring. The purpose of this report is to review the pharmacotherapy management of grade 4 OA Hip Dextra with comorbid HT and DMT2, assessing the safety, effectiveness, and role of clinical pharmacists in therapy optimization. A retrospective case study was conducted by analyzing the patient's medical records, including anamnesis, physical examination, laboratory, pharmacological therapy, and clinical response. The analysis was conducted based on the national guidelines of the Indonesian Ministry of Health, the 2021 National Formulary, PERKENI 2023, and PAPDI 2021. The patient was given combination therapy of NSAIDs, analgesics, prophylactic antibiotics, muscle relaxants, gastric protection, and supplementation for anemia. Therapeutic adjustments were made according to the patient's response and laboratory parameters. Clinical pharmacy monitoring ensures pain control, mobility, hemoglobin, and blood sugar. A multidisciplinary approach based on national guidelines has been shown to improve the safety and effectiveness of OA therapy with multiple comorbidities.
Resistensi Clopidogrel pada Pasien Penyakit Jantung Koroner di Asia Tenggara: Sebuah Narrative Review Luthfiana, Farisa
SOCIAL CLINICAL PHARMACY INDONESIA JOURNAL Vol 10, No 1 (2025)
Publisher : Universitas 17 Agustus 1945 Jakarta

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52447/scpij.v10i1.9135

Abstract

Clopidogrel is a commonly used antiplatelet agent for the prevention of thrombotic events in patients with coronary artery disease (CAD), particularly in acute coronary syndrome and after percutaneous coronary intervention. However, interindividual variability in clopidogrel response, known as clopidogrel resistance or high on-treatment platelet reactivity (HPR), is associated with increased risks of adverse cardiovascular outcomes. This issue is especially relevant in Southeast Asia, where genetic and clinical factors may influence drug response.Objective: This narrative review aims to summarize current evidence regarding the mechanisms, prevalence, and clinical implications of clopidogrel resistance in patients with coronary artery disease in Southeast Asia. Methods: A narrative review of peer-reviewed literature was conducted focusing on clopidogrel resistance, platelet reactivity, CYP2C19 genetic polymorphisms, and cardiovascular outcomes in Asian and Southeast Asian populations. Results:Evidence indicates that CYP2C19 loss-of-function alleles are highly prevalent in Southeast Asia, resulting in a substantial proportion of patients classified as intermediate or poor metabolizers. These genetic variants are associated with reduced clopidogrel activation, increased platelet reactivity, and a higher risk of major adverse cardiovascular events, including stent thrombosis and recurrent myocardial infarction. Non-genetic factors such as diabetes mellitus, drug–drug interactions, and medication non-adherence further contribute to clopidogrel resistance. Pharmacogenetic-guided antiplatelet therapy and the use of alternative P2Y12 inhibitors, such as ticagrelor or prasugrel, have shown potential to improve clinical outcomes. Conclusion:Clopidogrel resistance represents a significant clinical challenge among patients with coronary artery disease in Southeast Asia. Integration of pharmacogenetic-guided strategies may enhance the effectiveness of antiplatelet therapy in this region.
IDENTIFIKASI ADVERSE DRUG REACTION (ADR) OBAT ANTI TUBERKULOSIS PADA PASIEN TB DI RSUD PASAR REBO JAKARTA TIMUR Sari, Dini Permata; Silitonga, Julita; Luthfiana, Farisa; Anggraeni, Ria
JIFI (Jurnal Ilmiah Farmasi Imelda) Vol. 9 No. 2 (2026): JIFI (Jurnal Ilmiah Farmasi Imelda)
Publisher : Universitas Imelda Medan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52943/jifarmasi.v9i2.2044

Abstract

Tuberculosis (TB) remains a major public health problem in Indonesia, ranking second globally in TB burden. Although Anti-Tuberculosis Drugs (ATDs) are effective in curing TB, prolonged treatment and combination regimens may lead to Adverse Drug Reactions (ADRs), potentially affecting patient adherence and treatment outcomes. This study aimed to identify the types of ADRs experienced by TB patients undergoing ATD therapy at Pasar Rebo General Hospital, East Jakarta, and to analyze the relationship between age, gender, and duration of drug use with ADR occurrence. This research employed a descriptive-analytic retrospective design conducted from June to July 2025. A total of 60 adult TB patients receiving first-line ATD therapy (Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol) were included. Data were collected using questionnaires and analyzed using univariate and multivariate statistical methods with SPSS. Causality assessment of ADRs was performed using the Naranjo algorithm. The results showed that 88.33% of patients experienced ADRs. The most frequently reported symptoms were nausea (48.33%), rash/itching (28.33%), and joint pain (26.67%). Most ADRs were categorized as “Probable” based on the Naranjo score. Multivariate analysis revealed that gender was significantly associated with ADR occurrence (p = 0.041), while age and duration of drug use were not statistically significant. In conclusion, ADRs are common among TB patients receiving ATD therapy, with gastrointestinal and dermatological symptoms being the most prevalent. Gender appears to be an important predictor of ADR risk. Therefore, close clinical monitoring and gender-sensitive pharmacovigilance strategies are essential to ensure patient safety, improve adherence, and optimize TB treatment outcomes.